|
Feb 28
|
XOMA to Present at Upcoming Investor Conferences in March
|
|
Jan 11
|
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
|
|
Jan 2
|
XOMA Announces Stock Repurchase Program of up to $50 Million
|
|
Dec 20
|
XOMA Declares Quarterly Preferred Stock Dividends
|
|
Dec 19
|
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
|